Half a world away from Washington, Asia’s corporate titans are coming to grips with the new, or perhaps all too familiar, ...

In the Indian stock market, FIIs are booking profits, domestic investors are treading carefully, and valuations are stretched ...

Singapore drew S$21.9 billion ($16.2 billion) in investment commitments in 2024, slightly higher than 2023, the Economic ...

WIPO, which became a UN-specialized agency in 1974, has positioned itself as the leading force in global IP protection. Unlike TRIPS, which enforces trade-based IP rules, WIPO oversees 27 broad IP ...

Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

When Genentech licensed experimental drug vixarelimab from Kiniksa Pharmaceuticals KNSA-1.57%decrease; red down pointing triangle, its scientists thought they had a future lung medicine in their ...

But MPs warned that the regulator received 75 per cent of its funding from pharmaceutical companies and was too close to the industry to be truly independent when scrutinising safety and ...

Spanish renewables developer X-Elio has signed a virtual power purchase agreement (vPPA) with a cohort of pharmaceutical companies for a 369MW solar project in Spain. The deal was signed with the ...